# Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

> **NCT01044459** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 605 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Aclidinium Bromide 200 µg
- **DRUG:** Aclidinium Bromide 400 µg

## Key facts

- **NCT ID:** NCT01044459
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01044459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01044459, "Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01044459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*